Sammenlign metoder
Gennemgå dine valgte metoder side om side; rækker, der afviger, er fremhævet.
| Parkinson's Disease Questionnaire-39× | EORTC QLQ-C30× | |
|---|---|---|
| Fagområde | Sundhedsudfald | Sundhedsudfald |
| Familie | Process / pipeline | Process / pipeline |
| Oprindelsesår≠ | 1997 | 1993 |
| Ophavsperson≠ | Crispin Jenkinson et al. | Nico Aaronson et al. |
| Type | Self-report quality of life questionnaire | Self-report quality of life questionnaire |
| Oprindelig kilde≠ | Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age and Ageing, 26(5), 353-357. DOI ↗ | Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. DOI ↗ |
| Aliasser | PDQ-39, Parkinson's Disease Questionnaire, PDQ | QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale |
| Relaterede≠ | 4 | 5 |
| Resumé≠ | The PDQ-39 is the most widely used patient-reported outcome measure for Parkinson's disease quality of life. Developed by Crispin Jenkinson and colleagues in 1997, this 39-item self-report questionnaire comprehensively assesses how Parkinson's symptoms affect daily functioning, emotional well-being, stigma, social support, and cognitive-communication abilities. It is the recommended instrument in major Parkinson's disease clinical trials and forms a core component of outcome measurement in movement disorders. | The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care. |
| ScholarGateDatasæt ↗ |
|
|